LMR Partners’s Orchestra BioMed OBIO Stock Holding History

LMR Partners’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,015	Closed	-$196K	–	1040
2023 Q1	$196K	Buy	+10,015	New	+$116K	﹤0.01%	862
2022 Q3	–	Sell	-145,108	Closed	-$1.45M	–	1282
2022 Q2	$1.45M	Hold	145,108	–	–	0.02%	642
2022 Q1	$1.44M	Buy	+145,108	New	+$1.43M	0.02%	686

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFG

SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return

LMR Partners's OBIO Position: Q2 2023 in Review

LMR Partners sold out of Orchestra BioMed (OBIO) in Q2 2023, closing a stake of 10,015 shares — an estimated $196K sold.

LMR Partners first reported a position in OBIO in Q1 2022 and held it in 3 quarters. The position peaked at $1.45M in Q2 2022. 39 funds tracked by Wall St. Rank hold OBIO as of Q2 2023.

LMR Partners reported no remaining Orchestra BioMed position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 10,015 Orchestra BioMed shares in Q2 2023, an estimated $196K.
LMR Partners first reported a position in Orchestra BioMed in Q1 2022 and held it in 3 quarters.
LMR Partners's Orchestra BioMed position peaked at $1.45M in Q2 2022.
39 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.